Introduction
Hypertension is present in almost 80% of acute stroke patients and is known to increase the occurrence and severity of ischemic stroke (Li et al., 2005) . The newest clinical guidelines for management of patients with acute ischemic stroke, recommend only treating the most severely elevated pressures in the first 24 hours and then only decreasing MAP by 15% (Adams et al., 2007) . For patients with preexisting hypertension, there is support for restarting antihypertensive medications, but only after 24 hours (Adams et al, 2007) .
The consequences of hypertension before and after stroke can also be demonstrated in animals. Spontaneously hypertensive rats (SHR) exhibit more severe neurological deficits and edema formation (Slivka et al, 1995 ) and more frequently demonstrate extensive cerebral infarct damage than normotensive animals following permanent focal cerebral ischemia (Coyle, 1986; Barone et al, 1992) . However, the studies using SHR have yielded contradictory results regarding the influence of blood pressure on ischemic injury and prognosis. It has been postulated that antihypertensive drugs may reduce the pressuredependent cerebral blood flow to the ischemic penumbra, or conversely, poststroke hypertension may be deleterious and facilitate edema formation in the ischemic brain tissue (Harms et al, 2000) . It is hypothesized that in the SHR, stimulation of brain and cerebrovascular angiotensin II (Ang II) systems contributes to vasoconstriction, increased expression of proinflammatory factors, and increased microvessel permeability (Ito et al, 2001 ). In support, it has been demonstrated that Ang II AT 1 receptor blockade reduces blood pressure, This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on June 17, 2008 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from normalizes the brain microcirculation and decreases the vulnerability to stroke in chronically hypertensive rats (Ito et al., 2002; Ando et al., 2004; Zhou et al., 2005) . Acute and prolonged Ang II AT 1 receptor blockade prior to the onset of experimental stroke may contribute to the protection against brain ischemia and inflammation in the SHR (Nishimura et al., 2000; Zhou et al., 2006) . However, this protection with AT 1 receptor inhibition as a pretreatment is not directly correlated with blood pressure reduction (Ito et al., 2002) .
Recent studies from our laboratory showed that candesartan, an AT 1 receptor blocker, administered after reperfusion in acute ischemic stroke normalizes blood pressure, reduces neurovascular damage and improves outcome in normotensive male Wistar rats (Fagan et al., 2006) . The purpose of the present study was to assess whether or not candesartan at reperfusion will be similarly protective in SHRs, a model that is likely to be more clinically relevant.
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Methods
Animals
Male spontaneously hypertensive rats (SHR) 9-week-old, weighing ca. 200 g, were purchased from Charles River Breeding Company (Wilmington, Massachusetts, USA). After shipping, the animals were housed in individual plastic cages for 5 -6 days prior to the surgery and experimentation. The rats were provided food and water ad libitum, a 12:12-h light/dark cycle at 24°C, and 30-40% humidity. Rats were weighed and randomly assigned to each experimental group. When the rats reached body weight of ca. 240 g, they were instrumented for telemetry blood pressure monitoring, and when they further gained body mass to 275-300 g they were subjected to the experimental protocol. Usually, the rats were at 12-13 week of age at the time of the experimental cerebral ischemia or sham.
The Institutional Animal Care and Use Committee (IACUC) of the Charlie Norwood VA Medical Center in Augusta, Georgia approved all procedures, in accordance with the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health.
Blood pressure telemetry
Telemetry transmitters (Data Sciences International, St. Paul, Minnesota, USA) were implanted according to the manufacturer's specifications as described elsewhere (Fagan et al., 2006) . Briefly, the rats were anesthetized with sodium This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on June 17, 2008 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from pentobarbital (65 mg/Kg, i.p.; Abbott Laboratories, Chicago, Illinois, USA) and a midline incision was performed to expose the abdominal aorta. The exposed vessel was shortly occluded to allow insertion of the transmitter catheter into the abdominal aorta. Using tissue glue, the catheter was secured in place and the incision (abdominal muscle and skin) was sutured. Rats returned to their individual cages and were allowed to recover from surgery for 10 days. By placing rats on top of the telemetry receivers arterial pressure waveforms were continuously recorded throughout the study. Data were recorded every 10 minutes for several days before the stroke (or sham) and until the sacrifice at 24 hours after the onset of stroke.
Experimental cerebral ischemia
Animals were anesthetized with 2% isoflurane via inhalation. Cerebral ischemia was induced using the intraluminal suture middle cerebral artery occlusion (MCAO) model (Zea Longa et al., 1989) . The right middle cerebral artery (MCA) was occluded with 19-21 mm 3-0 surgical nylon filament, which was introduced from the external carotid artery lumen into the internal carotid artery to block the origin of the right MCA. The animals were kept under anesthesia for only 10 minutes for the surgical procedure. The suture was removed after 3 hours of occlusion and the animals were returned to their cages.
Prior to reperfusion, the animals were subjected to the test for assessment of neurological function. Immediately after reperfusion, either saline or doses of This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on June 17, 2008 as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Perimed Laser Doppler Perfusion Imaging hardware and software system (PeriScan PIM 3 System; Perimed AB, Stockholm, Sweden) was used to document reduction of flow due to MCAO. In a subset of animals (n=5), the skin was reflected, the bone cleaned and scans were performed at baseline, 5 minutes after the MCAO, 5 minutes after reperfusion (before drug administration) and prior to sacrifice at 24 hours. All using the same scale, images were saved and average perfusion units were documented in both hemispheres at each time point. All endpoints were assessed in a blinded fashion.
Neurological assessment
Neurological function was measured prior to reperfusion and at 24 hours (just before sacrifice) using the Bederson score (Bederson et al., 1986 ). An animal with no apparent deficits obtained a 0; the presence of forelimb flexion = 1; decreased resistance to push = 2; and circling = 3. A score of 3 is consistent with a middle cerebral artery occlusion. Only animals with a score of 3 prior to reperfusion were included in the analysis of infarct size, hemoglobin, and neurological function. In addition to the Bederson score, several other behavioral tests such as beam walk, paw grasp and elevated body swing test were This article has not been copyedited and formatted. The final version may differ from this version.
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Assessment of infarct size, edema and hemoglobin content
At 24 hours after the onset of MCAO, anesthesia was performed with Ketamine 44 mg/Kg and Xylazine 13 mg/Kg administered intra-muscularly, animals were then perfused with saline, sacrificed, and their brains were removed. The brain tissue was sliced into seven 2 mm-thick slices in the coronal plane and stained with a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Chemical Co., St. Louis, Missouri, USA) for 15-20 minutes. Images of the stained sections were taken. Using image analysis software (Zeiss-KS300, Oberkochen, Germany), infarction zones were measured and percentage infarct size corrected for edema was calculated. Edema was quantified as the difference in area between the hemispheres, expressed as a percent of the contralateral hemisphere. The ischemic and non-ischemic hemispheres of the slices for the enzyme-linked immunosorbent assay (ELISA) were separated and processed, using the non-ischemic side as a control. After homogenizing the TTC-stained slices in the core of the infarct and collecting the supernatants, ELISA was performed to measure the hemoglobin content of the brain tissue (Hilali et al., 2004) .
Statistical analysis
For blood pressure data, the average of all measurements prior to MCAO was the pre-stroke value. Values obtained during the 3 hours of MCAO were Within 1 h of ischemia, MAP of the rats increased from baseline (ca. 140 mmHg) to approximately 190 mmHg, and remained at that level until reperfusion (Fig. 2) . Reperfusion provoked a drop of MAP, and it was dramatically enhanced by candesartan treatment. The repeated measures ANOVA showed a significant interaction between treatment and time (p<0.0001). There were no significant differences among the groups for the pre-stroke and the MCAO values (Table 1) .
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Infarct size, hemispheric edema and behavior
Infarct size (Fig. 3A ) and brain edema ( Calculated edema revealed a similar reduction (23.3% in saline group vs. 18.3% in 0.3 mg/kg candesartan group). Table 3 shows that there are significant differences among the groups for infarct size (p=0.0004) and edema (p=0.023).
The candesartan 0.3 mg/Kg group had the lowest infarct size and edema, and was significantly different from the control group. Neither of the other two candesartan doses were different from the saline group.
Animals receiving candesartan showed significantly better neurologic function prior to sacrifice, assessed in the Bederson score (Fig. 4) as well as in beam walk (Fig. 5A ) and paw grasp (Fig. 5B) tests. In the elevated body swing test, all animals subjected to ischemia, regardless of the treatment upon reperfusion, revealed a consistent left-oriented circling. There were significant differences among the groups for post-stroke values of Bederson scores (p=0.0012) and paw grasp (p=0.005). Both the candesartan 0.3 mg/Kg and 1 mg/kg groups had Bederson and beam walk scores that were significantly better than the control group. Figure 6 shows the effect of three doses of candesartan on hemoglobin content in the ischemic brain tissue collected 24 h after the onset of stroke. As 
Effect of candesartan on hemoglobin content in the ischemic brain tissue
Cerebral Perfusion
In all 5 animals tested, MCAO resulted in consistent reductions in average perfusion units + standard error (493.5 + 25.7 baseline versus 352 + 23.4 after occlusion) in the ischemic hemisphere, which ranged from 41.1 to 68% of the contralateral hemisphere five minutes after occlusion. Perfusion was restored to relative hyperemia (521 + 25.8; average of 13.5% higher than contralateral ) in the five minutes after reperfusion ( Figure 7A ). Hyperemia was bilateral prior to sacrifice in the saline treated (no asymmetry) but asymmetry was maintained in the candesartan 0.3 mg/kg animals ( Figure 7B 
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Discussion
The optimal approach to management of elevated blood pressure during the acute stroke period is unclear (Adams et al., 2007) In line with the above, Engelhorn et al. (2004) found that post-ischemia treatment with candesartan (clinically relevant procedure similar to that applied in our present studies) at a dose that had no significant effect on blood pressure, reduced infarct size and improved neurological score. Also, early administration of candesartan (3 h after onset of ischemia) to normotensive rats has been shown to be neuroprotective, but only when excessive BP lowering is avoided (Brdon et al., 2007) . We are the first group to add the additional benefit of a reduction in vascular damage and hemorrhage to the benefits of candesartan in SHRs as well as identifying an interaction between preexisting hypertension and stroke in the response to BP lowering with candesartan. An interesting finding in our study of improved neurologic function with candesartan 1 mg/kg despite no histologic neuro-or vascular protection, suggests an additional beneficial effect of the drug on recovery and perhaps brain plasticity.
Our findings are limited by the nature of the model (mechanical versus embolic; SHR versus other models of hypertension), the short duration of followup (24 hours), and the inability to determine the mechanism of the protective effects seen. It is most likely that the protective effects of candesartan are multimodal, partly due to BP lowering and partly due to pleiotropic vascular protective effects. It is clear that blood pressure lowering after reperfusion protects the vasculature and is neuroprotective (Elewa et al., 2007) . Translating this to human stroke patients is complicated by the fact that premorbid conditions, such as vascular disease due to chronic hypertension, changes the sensitivity to a given dose of antihypertensive and may make it more likely to overshoot baseline values and eliminate the benefit. Restarting blood pressure medications in patients with acute stroke, as has been recently recommended (Adams et al., 2007) , may be perilous if the same pre-stroke doses are used.
More research is necessary to identify patients most likely to benefit from blood pressure lowering with candesartan after stroke. Time ( 
